1. Pink Sheet
  2. >>Geography
  3. >>Europe

‘Substantial’ Discount Helps Zolgensma Win Access In UK

 
• By Francesca Bruce

The English and Scottish health technology appraisal bodies NICE and the Scottish Medicines Consortium have given the green light to Novartis/Avexis’ costly gene therapy, Zolgensma.

Morning in Jebel Shams, Oman
NHS England 'moved mountains' to strike Zolgensma deal • Source: Shutterstock

Novartis AG/Avexis’ Zolgensma (onasemnogene abeparvovec) is to be reimbursed on the National Health Service in both England and Scotland.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography